Following the temporary suspension of vaccinations with the active ingredient from Johnson & Johnson in the USA, an advisory body to the US health authority CDC has spoken out in favor of collecting more information before making a recommendation on how to proceed. This was decided by the members of the committee on Wednesday after hours of discussion at a short-term emergency meeting. There should be another meeting in about a week, it said.
The CDC and the FDA had recommended a temporary suspension of vaccinations with the active ingredient from Johnson & Johnson on Tuesday after six cases of sinus vein thrombosis were recorded in the United States. The exposure was recommended out of “excessive caution,” it said. The US pharmaceutical company Johnson & Johnson then delayed the market launch of its vaccine in Europe and temporarily suspended all ongoing studies with vaccinations with the active ingredient.
Affected young women
So far, according to updated data, more than 7.2 million doses of the vaccine, which was approved in the US at the end of February and only takes one dose, have been injected in the US. According to the authorities, 6 women between the ages of 18 and 48 had sinus vein thrombosis between 6 and 13 days after the vaccination. In three cases, thrombocytopenia, i.e. a lack of blood platelets, was also reported. A woman died.